APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis

Experimental Neurology

Volumn 183, Issue 1, 2003, Pages 249-253

  Fukumoto, Hiroaki ^a   Ingelsson, Martin ^a   Gårevik, Nina ^b   Wahlund, Lars Olof ^b   Nukina, Nobuyuki ^c   Yaguchi, Yoshio ^d   Shibata, Masao ^d   Hyman, Bradley T ^a   Rebeck, G William ^a   Irizarry, Michael C ^a  

^a MA GenHosp   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d Medical & Biological Laboratories Co Ltd   (Japan)

Author keywords

Alzheimer's disease; Apolipoprotein E; Biomarkers; Cerebrospinal fluid; ELISA; Mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC RISK; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; BLOOD; CEREBROSPINAL FLUID; GENETICS; GENOTYPE; HETEROZYGOTE; PREDICTION AND FORECASTING; REFERENCE VALUE; RISK; SWEDEN; UNITED STATES;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MASSACHUSETTS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK; SWEDEN;

EID: 0042889048     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00088-8     Document Type: Article

References (44)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, Washington, DC.
2. Bellosta S., Nathan B.P., Orth M., Dong L.M., Mahley R.W., Pitas R.E. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol.Chem. 270:1995;27063-27071.
3. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8:1988;1-21.
4. Diedrich J.F., Minnigan H., Carp R.I., Whitaker J.N., Race R., Frey W., Haase A.T. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J. Virol. 65:1991;4759-4768.
5. Dooneief G., Marder K., Tang M.X., Stern Y. The Clinical Dementia Rating scale community-based validation of "profound" and "terminal" stages . Neurology. 46:1996;1746-1749.
6. Gong J.S., Kobayashi M., Hayashi H., Zou K., Sawamura N., Fujita S.C., Yanagisawa K., Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J. Biol. Chem. 277:2002;29919-29926.
7. Gregg R.E., Zech L.A., Schaefer E.J., Stark D., Wilson D., Brewer H.B. Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78:1986;815-821.
8. Hesse C., Larsson H., Fredman P., Minthon L., Andreasen N., Davidsson P., Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem. Res. 25:2000;511-517.
9. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J. Lipid Res. 31:1990;545-548.
10. Kowal R.C., Herz J., Goldstein J.L., Esser V., Brown M.S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86:1989;5810-5814.
11. LaDu M.J., Gilligan S.M., Lukens J.R., Cabana V.G., Reardon C.A., Van Eldik L.J., Holtzman D.M. Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70:1998;2070-2081.
12. Laskowitz D.T., Horsburgh K., Roses A.D. Apolipoprotein E and the CNS response to injury. J. Cereb. Blood Flow Metab. 18:1998;465-471.
13. Lefranc D., Vermersch P., Dallongeville J., Daems-Monpeurt C., Petit H., Delacourte A. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci. Lett. 212:1996;91-94.
14. Lehtimaki T., Pirttila T., Mehta P.D., Wisniewski H.M., Frey H., Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95:1995;39-42.
15. Linton M.F., Gish R., Hubl S.T., Butler E., Esquivel C., Bry W.I., Boyles J.K., Wardell M.R., Young S.G. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88:1991;270-281.
16. Mahley R.W. Apolipoprotein E cholesterol transport protein with expanding role in cell biology . Science. 240:1988;622-630.
17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlam M. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease . Neurology. 34:1984;939-944.
18. Merched A., Blain H., Visvikis S., Herbeth B., Jeandel C., Siest G. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J. Neurol. Sci. 145:1997;33-39.
19. Montine K.S., Bassett C.N., Ou J.J., Markesbery W.R., Swift L.L., Montine T.J. Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. J. Lipid Res. 39:1998;2443-2451.
20. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264:1994;850-852.
21. Nukina N., Uchida K., Sakamoto T., Ide K., Kanazawa I. Monoclonal antibody against the polymorphic site distinguishes apolipoprotein E4 from other isoforms. Biochem. Biophys. Res. Commun. 216:1995;467-472.
22. Ordovas J.M., Litwack-Klein L., Wilson P.W., Schaefer M.M., Schaefer E.J. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J. Lipid. Res. 28:1987;371-380.
23. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementiamild cognitive impairment (an evidence based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology . Neurology. 56:2001;1133-1142.
24. Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H. Lipoproteins and their receptors in the central nervous system characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain . J. Biol. Chem. 262:1987;14352-14360.
25. Rebeck G.W., Cheung B.S., Growdon W.B., Deng A., Akuthota P., Locascio J., Greenberg S.M., Hyman B.T. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci. Lett. 272:1999;155-158.
26. Rebeck G.W., Perls T.T., West H.L., Sodhi P., Lipsitz L.A., Hyman B.T. Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology. 44:1994;1513-1516.
27. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease allelic variation and receptor interactions . Neuron. 11:1993;575-580.
28. Saunders A., Strittmater W., Schmechel D., St. George-Hyslop P., Pericak-Vance M., Joo S., Rosi B., Gusella J., Crapper-MacLachlan D., Alberts M., Hulette C., Crain B., Goldgaber D., Roses A. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
29. Schiele F., De Bacquer D., Vincent-Viry M., Beisiegel U., Ehnholm C., Evans A., Kafatos A., Martins M.C., Sans S., Sass C., Visvikis S., De Backer G., Siest G. Apolipoprotein E serum concentration and polymorphism in six European countries the ApoEurope Project . Atherosclerosis. 152:2000;475-488.
30. Siest G., Bertrand P., Qin B., Herbeth B., Serot J.M., Masana L., Ribalta J., Passmore A.P., Evans A., Ferrari M., Franceschi M., Shepherd J., Cuchel M., Beisiegel U., Zuchowsky K., Rukavina A.S., Sertic J., Stojanov M., Kostic V., Mitrevski A., Petrova V., Sass C., Merched A., Salonen J.T., Tiret L., Visvikis S. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres the ApoEurope study. ApoEurope group . Clin. Chem. Lab. Med. 38:2000;721-730.
31. Siest G., Pillot T., Regis-Bailly A., Leininger-Muller B., Steinmetz J., Galteau M.M., Visvikis S. Apolipoprotein E an important gene and protein to follow in laboratory medicine . Clin. Chem. 41:1995;1068-1086.
32. Steinmetz A., Jakobs C., Motzny S., Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis. 9:1989;405-411.
33. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease . Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
34. Strittmatter W.J., Weisgraber K.H., Huang D., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid β peptide isoform specific effects and implications for late onset Alzheimer disease . Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102.
35. Tozuka M., Hidaka H., Miyachi M., Furihata K., Katsuyama T., Kanai M. Identification and characterization of apolipoprotein(AII-E2-AII) complex in human plasma lipoprotein. Biochim. Biophys. Acta. 1165:1992;61-67.
36. Uchida Y., Ito S., Nukina N. Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms. J. Clin. Lab. Anal. 14:2000;260-264.
37. Weintraub M.S., Eisenberg S., Breslow J.L. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J. Clin. Invest. 80:1987;1571-1577.
38. Weisgraber K.H. Apolipoprotein E distribution among human plasma lipoproteins role of the cysteine-arginine interchange at residue 112 . J. Lipid Res. 31:1990;1503-1511.
39. Weisgraber K.H., Innerarity T.L., Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257:1982;2518-2521.
40. Weisgraber K.H., Mahley R.W. Apoprotein (E - A-I1) complex of human plasma lipoproteins. 1. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J. Biol. Chem. 253:1978;6281-6288.
41. Weisgraber K.H., Mahley R.W., Kowal R.C., Herz J., Goldstein J.L., Brown M.S. Apolipoprotein C-1 modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related. J. Biol. Chem. 265:1990;22453-22459.
42. Weisgraber K.H., Shinto L.H. Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma impact on receptor binding activity . J. Biol. Chem. 266:1991;12029-12034.
43. Yamauchi K., Tozuka M., Hidaka H., Hidaka E., Kondo Y., Katsuyama T. Characterization of apolipoprotein E-containing lipoproteins in cerebrospinal fluid effect of phenotype on the distribution of apolipoprotein E . Clin. Chem. 45:1999;1431-1438.
44. Yamauchi K., Tozuka M., Nakabayashi T., Sugano M., Hidaka H., Kondo Y., Katsuyama T. Apolipoprotein E in cerebrospinal fluid relation to phenotype and plasma apolipoprotein E concentrations . Clin. Chem. 45:1999;497-504.